The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.
I’ve seen SOHO evolve over the dozen or so years since it was established. SOHO plays a unique role in bringing cutting-edge advances in hematologic malignancies to the broader hematology-oncology community.
The theme is both timely and important, and I would like to share my perspective as a clinician practicing in Europe on what collaborative science looks like from a European point of view.
SOHO 2026 Friday plenary features NIH scientist and aplastic anemia expert Dr. Neal S. Young. The plenary will take place at 1:47 pm Central time on September 11 in the General Assembly.
After years of awaiting results from clinical trials that included BTKi in frontline treatment combinations, the ECHO trial led to the FDA’s approval of the first BTKi in combination with chemoimmunotherapy.
Dr. Alderuccio highlighted data from the ECHELON-3 trial supporting FDA-approved brentuximab vedotin with lenalidomide and rituximab as an option that can be provided in any clinic. Other approved choices show limited durability.
These findings are clinically relevant in a highly curable disease that frequently affects younger adults. When selecting a treatment regimen for this patient population, it is important to balance durable disease control with preservation of physical function and QoL.
SOHO Insider is the official media platform of the Society of Hematologic Oncology. The SOHO Insider Editorial Board is comprised of leading hematologists. Learn more about our editorial board and SOHO Insider platforms.
To access the SOHO Career Center click the following link.
